Asia COVID-19 Culture and Poetry Editorials General United States World

90% Efficacy in Pfizer’s Covid Vaccine

Photo from Google Images

In the trial volunteers without evidence of prior infection of the virus, results from an interim analysis of a phase 3 study demonstrated 90% effectiveness. BTN162b2 is a messenger RNA-based vaccine candidate requiring 2 doses. Global phase 3 clinical trial began on July 27 and enrolled 43,538 participants to date, with 42% of enrollees having racial and ethically diverse backgrounds.

38,955 trial volunteers received the second dose of either vaccine or placebo by November 8, and an independent data monitoring committee (DMC) found the vaccine efficacy rate at above 90% 7 days after the second dose. This means protection was achieved 28 das after the first vaccine dose.

This vaccine has been developed on the genetic strategy, meaning that it introduces the gene that codes for the coronavirus spike protein into the cell. The cells will make the spike protein, which the immune system will recognize and create antibodies for.

About 94 people did get sick, but in general, the 90% effectiveness is a positive news.

So far, there has not been any serious safety concerns.

The study plants to continue to collect safety and efficacy data as planned, and companies plan to apply to the FDA for emergency use authorization soon after the required safety milestone is achieved.

However, the administering of this vaccine may prove to be a challenge, as the vaccine must be shipped and stored at -70 to -80 degrees celsius, meaning the product would have to be shipped on dry ice.

While this is good news, even if everything is done as scheduled, to include Americans being vaccinated later this year, it would still be many more months before there is widespread vaccination in the country.

It is still imperative that Americans use masks, contact tracing, social distancing, and hand washing to keep themselves safe.

Coree ILBO/ copyright (c) 2013-2020, All rights reserved.

This material may not be published, broadcast, rewritten or redistributed in whole or part with out the express written permission.

Leave a Reply

Your email address will not be published. Required fields are marked *

Confirm that you are not a bot - select a man with raised hand: